Etravirine in Treatment-Experienced Children and Adolescents
PIANO Trial
Etravirine in Treatment-Experienced Children & Adolescents

PIANO: Study Design

Study Design: PIANO

• **Background:** Phase 2, single-arm trial assessing safety and efficacy of etravirine in treatment-experienced, HIV-infected patients

• **Inclusion Criteria** (n = 101)
  - Children ≥6 and <12 years
  - Adolescents ≥12 and <18 years old
  - Treatment-experienced
  - No resistance to etravirine

• **Treatment Arms**
  - Etravirine 5.2 mg/kg bid + Investigator-selected optimized background regimen (OBR)

*OBT = ≥ 2 active ARVs, including a ritonavir-boosted PI and NRTIs +/- Enfuvirtide +/- Raltegravir

Etravirine in Treatment-Experienced Children & Adolescents

PIANO: Result

Week 24 and 48: Virologic Response (ITT Analysis, N=F)*

*ITT: Intent-to-Treat, N=F: Noncompleter=Failure

Etravirine in Treatment-Experienced Children & Adolescents

PIANO: Result

Week 48: Measures of Adherence

Etravirine in Treatment-Experienced Children & Adolescents

PIANO: Result

Week 48: Adverse Events

**Conclusions**: “Results with etravirine 5.2 mg/kg bid (with OBR) in this treatment-experienced paediatric population and etravirine 200 mg bid in treatment-experienced adults were comparable. Etravirine is an NNRTI option for treatment-experienced paediatric patients.”
Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.

*The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.*